Cancer history

A predictor of IPMN subtype and dysplastic status?

Rosalie A. Carr, Brandon A. Kiel, Alexandra M. Roch, Eugene P. Ceppa, Michael House, Nicholas Zyromski, Attila Nakeeb, C. Schmidt

Research output: Contribution to journalArticle

Abstract

Introduction: The aim of this study was to determine the association of PMH and FH of pancreatic (PDAC) and non-pancreatic cancers with IPMN malignant risk. Methods: A retrospective review of a prospective database of IPMN patients undergoing resection was performed to assess FH and PMH. Results: FH of PDAC was present in 13% of 362 included patients. Of these, 8% had at least one first degree relative (FDR) with PDAC. The rate of PDAC positive FH in non-invasive versus invasive IPMN patients was 14% and 8%, respectively (p = 0.3). In main duct IPMN patients, FH (44%) and PMH of non-pancreatic cancer (16%) was higher than that seen in branch duct IPMN (FH 29%; PMH 6%; p = 0.004 and 0.008). Conclusions: FH of PDAC is not associated with IPMN malignant progression. FH and PMH of non-pancreatic cancer is associated with main duct IPMN, the subtype with the highest rate of invasive transformation.

Original languageEnglish (US)
JournalAmerican Journal of Surgery
DOIs
StateAccepted/In press - Jan 1 2017

Fingerprint

Neoplasms
Databases

Keywords

  • Family history
  • IPMN
  • Malignant progression
  • Pancreatic ductal adenocarcinoma
  • Past medical history

ASJC Scopus subject areas

  • Surgery

Cite this

Cancer history : A predictor of IPMN subtype and dysplastic status? / Carr, Rosalie A.; Kiel, Brandon A.; Roch, Alexandra M.; Ceppa, Eugene P.; House, Michael; Zyromski, Nicholas; Nakeeb, Attila; Schmidt, C.

In: American Journal of Surgery, 01.01.2017.

Research output: Contribution to journalArticle

@article{f545829b187a4d22b5d03128426f6a2b,
title = "Cancer history: A predictor of IPMN subtype and dysplastic status?",
abstract = "Introduction: The aim of this study was to determine the association of PMH and FH of pancreatic (PDAC) and non-pancreatic cancers with IPMN malignant risk. Methods: A retrospective review of a prospective database of IPMN patients undergoing resection was performed to assess FH and PMH. Results: FH of PDAC was present in 13{\%} of 362 included patients. Of these, 8{\%} had at least one first degree relative (FDR) with PDAC. The rate of PDAC positive FH in non-invasive versus invasive IPMN patients was 14{\%} and 8{\%}, respectively (p = 0.3). In main duct IPMN patients, FH (44{\%}) and PMH of non-pancreatic cancer (16{\%}) was higher than that seen in branch duct IPMN (FH 29{\%}; PMH 6{\%}; p = 0.004 and 0.008). Conclusions: FH of PDAC is not associated with IPMN malignant progression. FH and PMH of non-pancreatic cancer is associated with main duct IPMN, the subtype with the highest rate of invasive transformation.",
keywords = "Family history, IPMN, Malignant progression, Pancreatic ductal adenocarcinoma, Past medical history",
author = "Carr, {Rosalie A.} and Kiel, {Brandon A.} and Roch, {Alexandra M.} and Ceppa, {Eugene P.} and Michael House and Nicholas Zyromski and Attila Nakeeb and C. Schmidt",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.amjsurg.2017.11.014",
language = "English (US)",
journal = "American Journal of Surgery",
issn = "0002-9610",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Cancer history

T2 - A predictor of IPMN subtype and dysplastic status?

AU - Carr, Rosalie A.

AU - Kiel, Brandon A.

AU - Roch, Alexandra M.

AU - Ceppa, Eugene P.

AU - House, Michael

AU - Zyromski, Nicholas

AU - Nakeeb, Attila

AU - Schmidt, C.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Introduction: The aim of this study was to determine the association of PMH and FH of pancreatic (PDAC) and non-pancreatic cancers with IPMN malignant risk. Methods: A retrospective review of a prospective database of IPMN patients undergoing resection was performed to assess FH and PMH. Results: FH of PDAC was present in 13% of 362 included patients. Of these, 8% had at least one first degree relative (FDR) with PDAC. The rate of PDAC positive FH in non-invasive versus invasive IPMN patients was 14% and 8%, respectively (p = 0.3). In main duct IPMN patients, FH (44%) and PMH of non-pancreatic cancer (16%) was higher than that seen in branch duct IPMN (FH 29%; PMH 6%; p = 0.004 and 0.008). Conclusions: FH of PDAC is not associated with IPMN malignant progression. FH and PMH of non-pancreatic cancer is associated with main duct IPMN, the subtype with the highest rate of invasive transformation.

AB - Introduction: The aim of this study was to determine the association of PMH and FH of pancreatic (PDAC) and non-pancreatic cancers with IPMN malignant risk. Methods: A retrospective review of a prospective database of IPMN patients undergoing resection was performed to assess FH and PMH. Results: FH of PDAC was present in 13% of 362 included patients. Of these, 8% had at least one first degree relative (FDR) with PDAC. The rate of PDAC positive FH in non-invasive versus invasive IPMN patients was 14% and 8%, respectively (p = 0.3). In main duct IPMN patients, FH (44%) and PMH of non-pancreatic cancer (16%) was higher than that seen in branch duct IPMN (FH 29%; PMH 6%; p = 0.004 and 0.008). Conclusions: FH of PDAC is not associated with IPMN malignant progression. FH and PMH of non-pancreatic cancer is associated with main duct IPMN, the subtype with the highest rate of invasive transformation.

KW - Family history

KW - IPMN

KW - Malignant progression

KW - Pancreatic ductal adenocarcinoma

KW - Past medical history

UR - http://www.scopus.com/inward/record.url?scp=85034759667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034759667&partnerID=8YFLogxK

U2 - 10.1016/j.amjsurg.2017.11.014

DO - 10.1016/j.amjsurg.2017.11.014

M3 - Article

JO - American Journal of Surgery

JF - American Journal of Surgery

SN - 0002-9610

ER -